David Cescon

基本信息

浏览量：17

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 291 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

631P Phase Ib Expansion Study of CX-5461 in Patients with Solid Tumours and BRCA2 And/or PALB2 Mutation

P.D. Soberanis Pina,S. Lheureux, H. Han, G. Shapiro,D.M. Provencher, L.S. Rosen, S. Sardesai, S. Taylor,D. Cescon, H.A. Alqaisi, S. Aparicio, P. Sabantini, T-I. Chao, C-E. Huang, M-C. Chen, L. Mahmud, X.Y. Ye,V. Bowering, A.M. Oza

Annals of Oncology (2024)

引用0浏览0引用

LBA2 Datopotamab Deruxtecan (Dato-Dxd) Vs Chemotherapy (CT) in Pretreated, Inoperable/metastatic HR+/HER2– Breast Cancer (BC): Additional Safety Analysis from TROPION-Breast01

K. Jhaveri,A. Bardia, S-A. Im,S. Pernas Simon,M. De Laurentiis, S. Wang, N. Martinez, G. Santos Borges,D.W. Cescon, M. Hattori,Y-S. Lu,E.P. Hamilton,J. Tsurutani,K. Kalinsky, D. Mapiye, R. Fairhurst, M.A. Munegowda, B. Xu,B. Pistilli,H.S. Rugo

ESMO Open (2024)

引用0浏览0引用

PLK4 As a Potential Target to Enhance Radiosensitivity in Triple-Negative Breast Cancer

Sierra Pellizzari,Vasudeva Bhat, Harjot Athwal,David W. Cescon,Alison L. Allan,Armen Parsyan

RADIATION ONCOLOGY（2024）

引用0浏览0WOS引用

45P Integrated Multi-Omic Analysis of HR+/HER2- Breast Cancer Cell Lines Resistant to CDK4/6 Inhibitors

C. Guarducci,D. Romagnoli,A. Nardone,C. Biagioni,M. Bonechi,G. Capaccioli,F. Galardi, F. Santaniello,L. Biganzoli,D.W. Cescon,R. Schiff,M. Lupien,M. Benelli,I. Migliaccio,L. Malorni

ESMO Open (2024)

引用0浏览0引用

Longitudinal ctDNA monitoring using a high sensitivity tumor-informed assay in patients with metastatic HR+/ HER2-breast cancer receiving endocrine therapy and CDK4/ 6 inhibitors

Jesus Fuentes-Antras,Mitchell J. Elliott,Philippe Echelard,Aaron Dou,Zachary Veitch,Philippe L. Bedard,Eitan Amir,Michelle B. Nadler,Nicholas Meti,Nancy Gregorio,Elizabeth Shah,Emily Van de Laar,Celeste Yu, Lisa Gates, Clodagh Murray, Christopher G. Smith, Amber Chevalier,Lillian L. Siu,Hal K. Berman,David W. Cescon

CANCER RESEARCHno. 6 (2024): 2429-2429

引用0浏览0引用

Ionizable Drugs Enable Intracellular Delivery of Co-Formulated Sirna

Kai V. Slaughter,Eric N. Donders, Michael S. Jones, Sami G. Sabbah,Mitchell J. Elliott,Brian K. Shoichet,David W. Cescon,Molly S. Shoichet

ADVANCED MATERIALS (2024)

引用0浏览0WOS引用

Abstract PO4-19-05: OptimICE-pCR: De-escalation of therapy in early-stage TNBC patients who achieve pCR after neoadjuvant chemotherapy with checkpoint inhibitor therapy (Alliance A012103)

Sara Tolaney,Karla Ballman,Charles M Perou,David Cescon,Margaret Gatti-Mays,Victoria Blinder,Shoshana Rosenberg,Elizabeth Mittendorf,Anna Weiss,Hope Rugo,Alice Ho,Dana Casey,Baljit Singh, Fabrice Smieliauskas,Yara Abdou,Vijay Damarla,Jane Meisel,Lisa Carey,Ann Partridge

Cancer Researchno. 9_Supplement (2024): PO4-19

引用0浏览0引用

David W. Cescon,Peter Schmid,Hope S. Rugo, Seock-Ah Im,Mastura Md Yusof,Carlos Gallardo,Oleg Lipatov,Carlos H. Barrios,Jose Perez-Garcia,Hiroji Iwata,Norikazu Masuda,Marco Torregroza Otero,Erhan Gokmen,Sherene Loi,Amin Haiderali,Xuan Zhou,Zifang Guo,Allison Martin Nguyen,Javier Cortes

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTEno. 5 (2024): 717-727

引用1浏览0WOS引用

Randomized Phase 3 Study of Datopotamab Deruxtecan Vs Chemotherapy for Patients with Previously-Treated Inoperable or Metastatic Hormone Receptor-Positive, HER2-negative Breast Cancer: Results from TROPION-Breast01

Aditya Bardia,Komal Jhaveri, Seock-Ah Im, Michelino De Laurentiis,Binghe Xu,Sonia Pernas, Giuliano Borges,David Cescon,Masaya Hattori,Yen-Shen Lu, Noelia Martinez-Janez,Erika Hamilton,Shusen Wang,Junji Tsurutani,Kevin Kalinsky,Lu Xu,Sabrina Khan,Neelima Denduluri,Hope Rugo,Barbara Pistilli

CANCER RESEARCHno. 9 (2024)

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn

助理教授

论文共 291 篇作者统计合作学者相似作者